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Purpose: To document survival for patients treated with stereotactic radiosurgery (SRS) 
alone for brain metastases either at initial presentation or for salvage in conjunction with 
other known prognostic factors in a single institutional community setting with compar-
ison to current literature.
Methods: All patients treated for brain metastases with SRS between October 2006 
and October 2013 were reviewed. We identified 91 patients treated with SRS alone for 
first brain metastatic event (FBME) and 87 patients treated with SRS for second brain 
metastatic event (SBME). We excluded the 14 patients treated with SRS for both FBME 
and SBME to satisfy the independence assumption for comparison of groups. Patient 
demographics, including age, gender, primary cancer type, presence of extracranial 
metastases, number of brain metastases, initial site of metastases (brain vs. other), 
recursive partitioning analysis (RPA), and Karnofsky Performance status (KPS) were 
documented.
results: There were no significant differences in overall survival for patients treated with 
SRS for FBME compared with SBME (log-rank p = 0.9347). Univariate and multivariable 
Cox regression modeling revealed KPS (p = 0.0003) and RPA (p = 0.0143) were the 
only independent prognostic factors for survival. Specifically, patients with RPA 1 had a 
61% decreased risk of death compared to those with RPA 3. Patients with RPA 2 had 
a 33% decreased risk of death compared to those with RPA 3. The 1-year survival rate 
was 36.5% for patients with RPA1, 33.3% for those with RPA 2, and 17.1% for those 
with RPA 3. Patients with KPS 90–100 had a 62% decreased risk of death compared to 
those with KPS < 70. The 1-year survival rate for patients KPS 90–100, 70–80, and <70 
were 60.7, 24.6, and 16.7%, respectively.
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inTrODUcTiOn
The incidence of brain metastases from all cancers is approxi-
mately 370,000 new cases in the United States per year (1). This 
increase is likely due to improvements in systemic therapy and 
use of MRI; however, the brain continues to be a sanctuary site 
for most chemotherapeutic agents (2). The treatment of brain 
metastases traditionally was limited to surgical resection and/or 
whole-brain radiotherapy (WBRT), with survival of non-surgical 
candidates approximately 3–4  months (2). With stereotactic 
radiosurgery (SRS), isolated brain metastases can be treated, and 
WBRT can be reserved for salvage reducing the risk of neurocog-
nitive decline (3).
Diagnosis-specific overall survival (OS) prognostication 
tools have been developed for the first metastasis found within 
the brain, which we label as first brain metastatic event (FBME) 
(4–6). Recursive partitioning analysis (RPA) reported by Gaspar 
et  al., created a regression tree according to prognostic sig-
nificance with the best survival observed in patients <65 years, 
Karnofsky Performance status (KPS) ≥70, controlled primary 
tumor, and with no extracranial metastases (Class I-median 
survival 7.1  months). The worst survival was seen in patients 
with KPS < 70 (Class III-median survival 2.3 months). All other 
patients had intermediate survival (Class II-median survival 
4.2  months) (4). The most specific prognostic assessment tool, 
the diagnosis-specific graded prognostic assessment (GPA), was 
published by Sperduto et al. for lung cancer where KPS, age, num-
ber of brain metastases, and presence of extracranial metastases 
were significant for survival in multivariate analysis. For renal cell 
and melanoma, only KPS and number of brain metastases was 
significant compared with breast and GI cancer where only KPS 
was significant (7, 8). Survival prognosticators for patients fac-
ing a second brain metastatic event (SBME) have been reported 
(9–11). The purpose of the current study is to document survival 
for patients treated with SRS alone for brain metastases either 
at initial presentation or for salvage in conjunction with other 
known prognostic factors, such as RPA in a single institutional 
community setting with comparison to current literature.
MaTerials anD MeThODs
All patients treated for brain metastases with SRS alone at 
Philadelphia CyberKnife between October 2006 and October 
2013 were reviewed. Patients treated with SRS as a boost after 
whole-brain radiation or SRS following surgical resection were 
excluded. We excluded nine patients lost to follow-up. We 
identified 91 patients treated with SRS for FBME and 87 patients 
treated with SRS for SBME, including 14 patients who received 
SRS for both FBME and SBME. We excluded the 14 patients 
from further analysis to satisfy the independence assumption. 
The remaining 77 patients treated with SRS for FBME and 73 
patients for SBME constitute the current study group. Seventy 
percent of patients (n = 51) who were treated with SRS for SBME 
had previously received WBRT with a median of 8.5 months from 
WBRT to SRS.
Approval for this study was granted by the Crozer-Keystone 
Health Care System Institutional Review Board (IRB#15-023) 
in accordance with institutional guidelines through expedited 
review by the IRB Chair on July 27, 2015. The informed consent 
requirement was waived by the Committee that approved the 
study, and all data used in this study were anonymized. This 
study is exempt from individual patient consent because of the 
retrospective nature of the review and the lack of risk associated 
with the project. Patients were explained the risks and benefits 
of participating, and all patients included had given written 
informed consent in accordance with the Declaration of Helinski.
All patients were simulated and treated with aquaplast mask 
immobilization. MRI with gadolinium and CT without contrast 
with 1.25 mm slices were merged for target definition. All patients 
were treated with the CyberKnife robotic system with skull track-
ing. Median SRS dose to PTV for patients treated with FBME 
and SBME was 20 Gy delivered in one fraction with a 1.25-mm 
margin around the CTV = GTV.
Patient demographics, including age, gender, primary cancer 
type, presence of extracranial metastases, number of brain metas-
tases, initial site of metastases (brain vs. other), RPA, and KPS, 
were documented. Follow-up and survival data were collected 
through various sources, including radiation oncology, hospital 
and referring physician charts, electronic medical records, and 
obituaries. Patients were considered lost to follow-up if no infor-
mation could be found regarding survival from the above sources, 
including contact with referring physician and attempts to con-
tact patient at home. Patients were followed every 3 months with 
MRI of the brain with gadolinium by the patient’s neurosurgeon, 
radiation oncologist, or medical oncologist. Date of death or date 
of last follow-up was recorded for all patients.
Descriptive statistics were used to summarize patient demo-
graphics and treatment characteristics. Continuous variables 
were described with means, SDs, medians, and interquartile 
ranges, while categorical variables were described with frequen-
cies and percentages. Survival was estimated from the end of SRS 
to last follow-up or death. Fisher’s exact test was used to compare 
conclusion: No difference in survival was noted for FBME and SBME with performance 
status, the single most important prognostic factor following SRS. Aggressive treatment 
should be considered for patients with good performance status regardless if presenting 
with FBME or SBME. Our results are consistent with single, multi-institutional, and ran-
domized trials after literature review.
Keywords: brain metastases, recurrent brain metastases, stereotactic radiosurgery, salvage stereotactic 
radiosurgery















 90–100 28 (18.7) 18 (23.4) 10 (13.7)
 70–80 78 (52.0) 44 (57.1) 34 (46.6)




 1 26 (17.3) 8 (10.4) 18 (24.7)
 2 81 (54.0) 54 (70.1) 27 (36.9)
 3 43 (28.7) 15 (19.5) 28 (38.4)
Primary location [N (%)] 0.0141
 Lung 83 (55.3) 41 (53.2) 42 (57.5)
 Breast 20 (13.3) 9 (11.7) 11 (15.1)
 Melanoma 13 (8.7) 12 (15.6) 1 (1.4)
 Other 34 (22.7) 15 (19.5) 19 (26.0)
Gender [N (%)] 0.0035
 Male 76 (50.7) 30 (39.0) 46 (63.0)
 Female 74 (49.3) 47 (61.0) 27 (37.0)
Age [Mean (SD)] 61.3 (13.4) 63.6 (14.0) 58.8 (12.4) 0.0274
Age [N (%)] 0.0133
 ≤65 87 (58.0) 37 (48.1) 50 (68.5)
 >65 63 (42.0) 40 (52.0) 23 (31.5)
Initial metastases [N (%)] 0.2496
 Brain 87 (58.0) 41 (53.2) 46 (63.0)
 Other 63 (42.0) 36 (46.8) 27 (37.0)
Number of metastases 
[N (%)]
0.4805
 1 or 2 105 (70.0) 56 (72.7) 49 (67.1)




 Present 77 (51.3) 39 (50.6) 38 (52.1)
 Absent 73 (48.7) 38 (49.4) 35 (47.9)
*p-Value based on two-sample T-test for continuous variable (age) and Fisher’s exact 
tests for categorical variables.
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the distribution of prognostic factors between FBME and SBME 
groups. OS was estimated using Kaplan–Meier methodology with 
group comparisons accomplished using log-rank statistics. To 
assess the individual impact of prognostic factors on OS from the 
time of SRS treatment in this patient population, univariate Cox 
proportional hazards (PH) models were examined. Hazard ratios 
and their 95% confidence intervals were estimated. Backwards 
selection was employed to fit multivariable Cox PH models con-
sidering all prognostics factors until all demonstrated significance 
at the 0.05 level. Due to collinearity between RPA and KPS, two 
separate multivariable Cox PH models were built considering 
either factor. Statistical analyses were accomplished using SAS 9.4.
resUlTs
Demographics
Primary cancers included lung (n = 83), breast (n = 20), mela-
noma (n = 13), and other (n = 34) (Table 1). Fifty percent of the 
other primary cancers category included colorectal and renal cell 
primaries. Patients treated with SRS for FBME were significantly 
older (63.6 vs. 58.8 years, p = 0.0274) with better performance 
status (19.5 vs. 38.4% RPA 3, p =  0.0002 and 19.5 vs. 39.7% 
KPS <  70, p =  0.0191), mostly of female gender (61 vs. 37%, 
p = 0.0035), and were diagnosed more frequently with primary 
melanoma (15.6 vs. 1.4%, p = 0.0141) compared to those treated 
for SBME (Table 1).
Overall survival
Median follow-up for the entire group was 6.08  months (IQR: 
3.02–13.22). There were 138 deaths out of 150 patients observed 
during the follow-up period. Median follow-up of alive patients is 
18.28 months (IQR: 7.43–24.49). OS for entire group of patients 
was 29.3% at 1 year, 12.4% at 2 years, and 3.9% at 3 years. There 
were no significant differences in OS between patients treated 
with SRS for FBME and SBME (Figure 1, log-rank p = 0.9347). 
However, significant differences in OS were found in patients 
with KPS 90–100 vs. KPS 70–80 vs. KPS < 70 (Figure 2, log-rank 
p =  0.0007). Median OS in months for patients reporting KPS 
90–100 was 13.28 compared to 6.05 and 4.96 for patients with 
KPS 70–80 and KPS < 70, respectively. Significant differences in 
OS were also found with patient RPA stages (Figure 3, log-rank 
p = 0.0126). Median OS in months was greater among patients 
with RPA 1 at 8.88 compared to 7.13 and 4.96 for patients with 
RPA 2 and RPA 3, respectively.
Univariate Cox regression modeling (excluding the 14 patients 
in both the FBME and SBME groups) revealed KPS and RPA 
were significantly associated with OS at the 0.05 level (Table 2). 
Primary tumor location was not significant in the univariate 
analysis; however, median survival in months was greater among 
patients with breast cancer compared to lung cancer and mela-
noma (7.40 vs. 5.82 vs. 4.93, respectively). Gender, site of initial 
metastasis, number of brain metastases at time of treatment, pres-
ence of extracranial metastases, and age were also not significant 
prognostic factors in univariate analyses.
Multivariable analysis (MVA) utilizing manual backward 
selection considering all factors revealed either RPA (p = 0.0143) 
or KPS (p = 0.0003) to be the only independent prognostic factors 
for survival in their respective models. Specifically, patients with 
RPA 1 had a 61% decreased risk of death compared to those with 
RPA 3 [HR: 0.387, HR 95% CI: (0.223–0.669)]. Patients with RPA 
2 had a 33% decreased risk of death compared to those with RPA 
3 [HR: 0.668, HR 95% CI: (0.447–1.000)]. The 1-year survival rate 
was 36.5% for patients with RPA1, 33.3% for those with RPA 2, 
and 17.1% for those with RPA 3. Patients with KPS 90–100 had 
a 62% decreased risk of death compared to those with KPS < 70 
[HR: 0.379, HR 95% CI: (0.237–0.607)]. The 1-year survival rate 
for patients KPS 90–100, 70–80, <70 were 60.7, 24.6, and 16.7%, 
respectively.
DiscUssiOn
Our results are consistent with previous reports of SRS alone 
for FBME in both a multi-institutional review and randomized 
controlled trial. Sneed et al. reported a review of 10 institutions 
FigUre 2 | Kaplan–Meier overall survival estimates for all patients by Karnofsky Performance status (p = 0.0007).
FigUre 1 | Kaplan–Meier overall survival estimates for patients treated with stereotactic radiosurgery for first brain metastatic event (FBMe) and 
second brain metastatic event (sBMe) (p = 0.9347).
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(268 patients) treated with SRS alone for FBME. Median survival 
was 8.2 months with 1-year actuarial survival of 38% (12). In a 
controlled randomized trial of SRS ± whole-brain radiation for 
FBME, Aoyama reported median survival of 8.0  months and 
1-year actuarial survival of 28.4% for SRS alone (100% KPS > 70), 
which compares favorably with our median survival of 6 months 
and 1-year actuarial survival of 29% (80.5% KPS > 70) (13).
Our median survival and 1-year actuarial survival of SRS 
alone for SBME is comparable to Kurtz et  al. who reported a 
median survival of 11.7 months after SRS for SBME in a group of 
healthier patients (87% ECOG 0-1/KPS 70–100 compared with 
60% for the current trial), most of whom received WBRT for 
FBME (81.1%). Kurtz et al. suggested a longer time from initial 
treatment with radiation to salvage SRS greater than 265  days, 
extracranial disease control, and younger age was predictive of 
better survival (9).
In the present study, we found RPA class and KPS to be the 
only significant prognostic factors for predicting survival from 
both FBME and SBME in MVA. We understand that we may 
be lacking power to find multiple prognostic factors in our 
multivariable analyses. Performance status has consistently been 
shown to be a significant prognostic factor for brain metastases, 
with poorer performance status correlated with poorer OS. Sneed 
et al  reported a review of 10 institutions (268 patients) treated 
with SRS alone for FBME. They confirmed RPA class as a sig-
nificant prognostic factor with median survival of 14 months for 
RPA 1, 8.2 months for RPA 2, and 5.3 months for RPA 3 (12). 
Kurtz et al. reported RPA to be a significant prognosticator for 
FigUre 3 | Kaplan–Meier overall survival estimates for all patients by recursive partitioning analysis (rPa) (p = 0.0126).
TaBle 2 | Univariate cox proportional hazards model results for all 
patients.
Parameter* hr hr 95%ci p-Value
Karnofsky Performance status 0.0003
 90–100 0.681 0.457 1.014 0.0587
 70–80 0.379 0.237 0.607 <0.0001
Recursive partitioning analysis 0.0143
 1 0.565 0.348 0.919 0.0214
 2 0.581 0.394 0.857 0.0062
Primary location 0.5579
 Breast 1.250 0.691 2.259 0.4603
 Lung 1.282 0.866 1.899 0.2149
 Melanoma 1.460 0.778 2.740 0.2390
Gender
 Female 0.931 0.669 1.297 0.6739
Age
 ≤65 1.090 0.776 1.533 0.6185
Brain metastatic event
 First brain metastatic event 1.014 0.730 1.408 0.9333
Initial metastasis
 Brain 1.070 0.763 1.500 0.6953
Extracranial metastases
 Present 0.930 0.664 1.303 0.6723
Number of metastases
 1 or 2 1.196 0.828 1.729 0.3402
*Reference groups: KPS ≤ 70, RPA = 3, primary location = others, gender = male, 
age > 65, brain metastatic event = SBME, extracranial metastases = absent, initial 
met = others, number of metastases = 3 or more.
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SBME patients in univariate but not MVA (9). Bhatnagar et al. 
reported their gamma knife radiosurgery experience for 4 or 
more brain metastases treated in one procedure, which included 
SRS alone and SRS boost after whole-brain radiation (FBME) and 
SRS for brain failure after whole-brain radiation (SBME). In this 
study, MVA revealed not only RPA but also age, total treatment 
volume, and marginal dose to be significant prognostic factors 
for survival (14). Shultz et al. reported the outcome of repeat SRS 
deferring whole-brain radiation for SBME and also found KPS 
and GPA score in addition to aggregate tumor volume and histol-
ogy to be significant for survival in MVA (10). More recently, 
Shen et al. reported patients with SBME treated with at least 2 
courses of SRS without whole-brain radiation. On MVA, ECOG 
performance status as well as controlled extracranial disease and 
interval between initial and second SRS > 6 months correlated 
with improved survival (11).
Overall survival for both FBME and SBME in our study was 
not significantly different with a median of 6.77 months, which is 
comparable to the 7.23 month median OS observed in the RTOG 
analysis that led to creation of the DS-GPA. This RTOG analysis 
had a similar percentage of patients who received WBRT in our 
study (70 vs. 76%) as treatment for FBME (8). Even though SBME 
patients in the current study had poorer performance status and 
thus would predict poorer OS, OS was not different to FBME. 
This may be related to other factors which could not be accounted 
for such as higher percentage of melanoma patients in the FBME 
group with median survival of only 5.82 months. FBME patients 
in our study were more likely female and older compared with 
the SBME group, which also may have contributed to the similar 
median survivals between the groups. Female and younger 
patients had slightly longer median survival but no difference 
in 1 or 2 year survival in the current analysis (data not shown). 
In contrast, Yamamoto et al. in a multi-institutional prospective 
observational study of 1,194 patients with FBME and 1–10 brain 
metastases, found female sex and age <65 to be strong prognos-
ticators for improved survival after treatment with SRS alone in 
multivariate analysis as important as KPS (15).
cOnclUsiOn
Despite the significant distribution difference in demographic 
and clinical characteristics between the FBME and SBME treat-
ment groups, no difference in OS was observed for the two groups 
when treated with SRS. RPA and KPS were shown independently 
by MVA to be the only significant prognosticator for survival after 
SRS. Review of the literature suggests SRS is an acceptable treat-
ment for patients with FBME and SBME with improved outcome 
for those with good performance status. Aggressive treatment 
should be considered for patients with brain metastases regard-
less of presenting with FBME or SBME with good performance 
status.
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